Cite

HARVARD Citation

    Tilanus-Linthorst, M. et al. (2021). FaMRIsc trial shows: MRI breast screening for women with ≥20% lifetime risk is also cost-effective in Europe. European journal of surgical oncology. 47 (2), pp. e19-. [Online]. 
  
Back to record